Codexis Inc. (CDXS)

13.90
NASDAQ : Process Industries
Prev Close 14.10
Day Low/High 13.80 / 14.25
52 Wk Low/High 3.95 / 14.45
Avg Volume 420.60K
Exchange NASDAQ
Shares Outstanding 53.24M
Market Cap 750.68M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Codexis Reaches Analyst Target Price

Codexis Reaches Analyst Target Price

In recent trading, shares of Codexis Inc have crossed above the average analyst 12-month target price of $10.00, changing hands for $10.40/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Codexis Reaches Analyst Target Price

Codexis Reaches Analyst Target Price

In recent trading, shares of Codexis Inc have crossed above the average analyst 12-month target price of $8.50, changing hands for $8.80/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Tough Day for Apple and Airlines

Price action isn't a sign of bearishness.

Codexis Reaches Analyst Target Price

Codexis Reaches Analyst Target Price

In recent trading, shares of Codexis Inc have crossed above the average analyst 12-month target price of $7.38, changing hands for $7.85/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Codexis Obtains Court Order Awarding Summary Judgment Of Patent Infringement Against EnzymeWorks

Codexis Obtains Court Order Awarding Summary Judgment Of Patent Infringement Against EnzymeWorks

Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, on Tuesday secured a federal court order awarding it summary judgment on 10 claims of patent infringement it brought in a lawsuit against Suzhou,...

Codexis Signs Second Multi-Year Agreement In Food Industry With Tate & Lyle

Codexis to Research and Develop Novel Enzymes Supporting Tate & Lyle's Food Ingredient Growth Strategies

TheStreet Quant Rating: D (Sell)